SNRS- Sunrise Technologies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies

SNRS 0.000001000

0.0%

Jun 6 11:01 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe who wrote (757)	4/21/1998 6:56:00 PM
From: Colby	Read Replies (2) of 4140

Joe, I agree with you completely. Knowing the little I do know about the procedures, there is now way one would choose the invasive over the non-invasive. However, I think the majority of patients will learn their options through their doctor. Which is he/she using? If VISX comes to market first, or if worse, they can modify their existing machines to do both techniques, their is incentive for the doctor to stick with VISX laser. He doesn't have to be retrained and he can work on both near and farsighted patients. I am not saying SNRS will not be able to penetrate the market succesfully, but it may take more time and money if VISX is approved first. Getting to market first is a huge advantage, especially if the product gives a doctor twice the capabilities. If VISX doesn't get approval for Hyperopia, then all the above is moot. I am just speculatin' for the sake of discussion. Thanks for the response, Colby

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next